Here are bills introduced by Chris Collins that could have impacted firms like Innate Immunotherapeutics.
• The 340B Protection and Accountability Act of 2019: Introduced on March 6 of this year, this bill would overhaul a government program that offers discount drugs to hospitals and clinics that serve large numbers of poor people. The bill called for fees on the medical institutions that use the program – a move that could curtail its use and boost profits for drug companies.
• The Drug Discount Accountability Act of 2018: Introduced on June 27, 2018, this was an earlier, bare-bones attempt to reform the 340B program to make it more profitable for pharmaceutical companies.
• The Patient Safety and Toxicology Modernization Act of 2017: Introduced on May 19, 2017, this bill would force the Food and Drug Administration to issue guidance on new ways to test the effectiveness and toxicology of new medications.
• The Patient Safety and Toxicology Modernization Act of 2016: Introduced on Dec. 7, 2016, this was an earlier version of the bill Collins wrote in 2017 regarding federal guidelines for the testing of new drugs.
• Amending the Public Health Service Act with respect to the Silvio O. Conte Senior Biomedical Research Service: This May 19, 2015, proposal – which later passed as part of the 21st Century CURES Act – would lift the cap limiting the number of senior researchers the FDA could hire.
• Amending the Federal Food, Drug, and Cosmetic Act with respect to broader application of Bayesian statistics and adaptive trial designs: Introduced on May 19, 2015, this legislation would have forced the FDA to issue guidance regarding alternative statistical methods that could be used in determining the effectiveness of new drugs. Similar changes were included in the 21st Century Cures Act.
• The Clinical Trials Modernization Act of 2015: Introduced on Feb. 25, 2015, this proposal is an earlier version of Collins’ legislation forcing the FDA to set rules regarding the use of alternative statistical methods in clinical trials of new drugs.